EMA's Medical Literature Monitoring Service Creates New Complexities For Pharma
This article was originally published in SRA
Executive Summary
Several drug companies are struggling to align their processes with the European Medicines Agency's new medical literature monitoring (MLM) service that was launched earlier this year to reduce the administrative burden associated with monitoring and reporting of suspected adverse reactions from drugs containing certain active substances1,2.
You may also be interested in...
Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.
EMA Tackles Complexities Introduced By Literature Monitoring Service
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.